ZEBETA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEBETA (ZEBETA).
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
| Metabolism | Hepatic metabolism via CYP2D6 to active metabolite (N-dealkylated product). |
| Excretion | Approximately 50% of an oral dose is excreted unchanged in urine; the remainder is hepatically metabolized with biliary excretion of metabolites contributing to fecal elimination. |
| Half-life | Terminal elimination half-life is 12–15 hours in patients with normal renal function, allowing once-daily dosing. |
| Protein binding | Approximately 50% bound to serum albumin. |
| Volume of Distribution | Volume of distribution is about 8–10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 50–60% due to first-pass metabolism. |
| Onset of Action | Oral: Antihypertensive effect begins within 1–2 hours. |
| Duration of Action | Duration of antihypertensive effect is approximately 24 hours, supporting once-daily administration. |
| Molecular Weight | 397.5 |
Initial dose 5 mg orally twice daily; may increase to 10 mg twice daily after 2 weeks; maximum 20 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50%. GFR <30 mL/min: use with caution; not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Start at 5 mg once daily; increase cautiously; monitor heart rate and blood pressure closely. |
| 1st trimester | Use only if potential benefit justifies risk to fetus; associated with fetal bradycardia and intrauterine growth restriction. |
| 2nd trimester | Monitor fetal heart rate and growth; may cause fetal bradycardia and preterm labor. |
| 3rd trimester | Avoid due to risk of neonatal bradycardia, hypotension, and hypoglycemia; discontinue or use with caution. |
Clinical note
Comprehensive clinical and safety monograph for ZEBETA (ZEBETA).
| Placental transfer | Crosses placenta; achieves fetal concentrations approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts; monitor infant for bradycardia and hypotension. |
| Lactation Rating |
■ FDA Black Box Warning
Abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease.
| Serious Effects |
Sinus bradycardiaHeart block greater than first degreeCardiogenic shockSevere asthmaDecompensated heart failureHypersensitivity to carvedilol or any component
| Precautions | Do not abruptly discontinue; taper over 1-2 weeks., Use with caution in patients with bronchospastic diseases (e.g., asthma) due to relative beta-2 blockade., May mask symptoms of hypoglycemia and thyrotoxicosis., Use with caution in patients with peripheral vascular disease., May cause bradycardia and hypotension. |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol consumption which may enhance hypotensive effects. Grapefruit juice has not been reported to interact, but caution if hypotension is a concern. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity and fetotoxicity at high doses. Second/third trimesters: Risk of fetal bradycardia, hypotension, hypoglycemia, and intrauterine growth restriction due to β-blockade. Use only if potential benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of heart failure. Fetal: Heart rate and growth via ultrasound; auscultation for bradycardia. Newborn: Observe for bradycardia, hypoglycemia, and respiratory depression for 48 hours post-delivery. |
| Fertility Effects | No well-controlled studies in humans. Animal data show no significant impairment of fertility at clinically relevant doses. Theoretical risk of reduced uterine blood flow; clinical significance unknown. |
| Clinical Pearls | ZEBETA (bisoprolol) is a cardioselective beta-1 blocker. Titrate slowly due to risk of bradycardia and hypotension. Do not discontinue abruptly; taper over 1-2 weeks to avoid rebound hypertension. Use with caution in asthma/COPD as it may increase bronchospasm, though less than non-selective beta blockers. Monitor heart rate and blood pressure regularly. In heart failure, initiate at low dose (1.25 mg) and up-titrate every 2 weeks as tolerated. |
| Patient Advice | Take exactly as prescribed, usually once daily, with or without food. · Do not stop taking abruptly as this may worsen heart condition or cause withdrawal symptoms like increased heart rate and blood pressure. · Avoid alcohol and over-the-counter decongestants, which can reduce effectiveness or increase side effects. · Monitor for signs of low heart rate (dizziness, fatigue, fainting) and slow breathing; report to doctor. · Inform all healthcare providers that you are taking bisoprolol before surgery or dental procedures. · If you miss a dose, skip it if close to next dose; do not double dose. |